OfferingRegistry
Offerings / Regulation CF / Barricade Therapeutics Corp.

Barricade Therapeutics Corp.

Regulation Crowdfunding offering on StartEngine · Form C filed March 2, 2026 · Fort Worth, Texas

Convertible noteEarly revenueCorporation, DelawareHealthcareBiotechnology drug development (oncology and neurology)

Barricade Therapeutics Corp., a Delaware corporation based in Fort Worth, Texas, develops drug candidates for oncology and neurology using its TASIN platform, with lead candidate BT-1501 targeting colorectal cancer with the APCmut gene. The company was incorporated on November 7, 2017, is pre-revenue and has not yet filed an IND, and is offering up to $1,235,000 of convertible promissory notes with a $20,000 minimum target.

Registry notesRelated-party dealings include IT support services provided by family member Jay Thapar, with $15,396 stated outstanding in one place and $3,847 in another, and a $10,000 loan from officer Neil Thapar that was repaid with interest in January 2025. The filing states $2.429 million of convertible notes outstanding, which excludes the $250,000 note sold July 23, 2025, and 839,563 shares is about 12.65% of the 6,634,643 shares outstanding rather than the 20.21% stated.

Profile details below were extracted automatically from the issuer's filing documents. Figures in the financial table come directly from the SEC's structured Form C data.

Offering terms

Security
Convertible Note
Maximum
$1,235,000.00
Price
Not stated per unit
Pricing method
N/A
Deadline
April 30, 2026
Oversubscriptions
Accepted
Intermediary
StartEngine Primary, LLC
Broker-dealer, SEC file 008-70060
Intermediary fee
7 - 13 percent
Intermediary equity
One percent (1%) of securities of the total amount of investments raised in the offering, along the same terms as investors.

Financials as filed

ItemMost recent FYPrior FY
Revenue$249,853$988,125
Cost of goods sold$0$0
Net income (loss)-$935,689-$17,008
Total assets$76,373$725,114
Cash and equivalents$10,832$493,663
Accounts receivable$0$0
Short-term debt$433,543$329,126
Long-term debt$2,969,312$2,786,781
Taxes paid$0$0

Two fiscal years as reported on the Form C cover sheet. 1 employees. Offered in 52 states.

Use of proceeds

At the $20,000 target: StartEngine platform fees 7.5% and general and administrative (salaries, intellectual property and legal fees, operations) 92.5%. At the $1,235,000 maximum: StartEngine platform fees 7.5%, Phase 1 clinical trial 37.5%, GMP manufacture of BT-1501 10.0%, research and development 22.0%, and general and administrative 23.0%. The filing states that some proceeds may be used for CPRIT matching funds.

Valuation

Valuation cap of $18,000,000 and a 20.0% discount to the price in a qualified financing of $10,000,000 or more. The cap was set internally by the company, is not based on a third-party valuation, and is not a current valuation. Additional bonus discounts apply: loyalty bonus of 20%, early bird bonuses of 10% to 30%, flash perks of 10%, tiered amount bonuses of 5% to 20%, and a 10% StartEngine Venture Club bonus. No separate pre-money valuation is stated. Interest accrues at 8.0% per year and the maturity date is January 31, 2028.

Prior raises

Not stated

Financial statements

Not stated. The filing refers to financial statements at the end of the offering memorandum, but no audit or review report or preparer is identified in the provided text.